Although RAS mutations alone are insufficient to drive full malignant transformation, the presence of co-occurring mutations, particularly TERT promoter mutations, has been linked to more aggressive tumor phenotypes and increased mortality in RAS-mutant DTCs (41, 42). The gene discussed is TERT; the disease is neoplasm.